Table 1.
Comparisons of clinicopathologic and treatment characteristics by era
| Characteristics | Pre-Trastuzumab Era | Trastuzumab Era | p-value |
|---|---|---|---|
| |
n = 128 |
n = 441 |
|
|
Age (years) |
0.017 |
||
| <65 |
104 (81%) |
345 (78%) |
|
| ≥ 65 |
24 (19%) |
96 (22%) |
|
| Median |
53 (26–81) |
55 (29–91) |
|
|
M1 at diagnosis |
<0.001 |
||
| Yes |
5 (4%) |
113 (26%) |
|
| No |
115 (90%) |
256 (58%) |
|
| Unknown |
8 (6%) |
72 (16%) |
|
|
Tumor grade |
0.084 |
||
| 1 |
0 (0%) |
13 (3%) |
|
| 2 |
24 (19%) |
106 (24%) |
|
| 3 |
95 (74%) |
315 (71%) |
|
| Unknown |
9 (7%) |
7 (2%) |
|
|
Hormone receptor status |
0.83 |
||
| ER+ |
51 (40%) |
180 (41%) |
|
| ER- |
68 (53%) |
249 (57%) |
|
| Unknown |
9 (7%) |
12 (3%) |
|
|
HER2 status |
<0.001 |
||
| Positive |
33 (26%) |
176 (40%) |
|
| Negative |
87 (68%) |
212 (48%) |
|
| Unknown |
8 (6%) |
53 (12%) |
|
|
Time from diagnosis to BM (years) |
|||
| Median |
3.3 |
2.3 |
|
|
KPS at BM |
0.76 |
||
| <70 |
47 (37%) |
170 (38%) |
|
| ≥70 |
81 (63%) |
271 (62%) |
|
|
Number of BM |
0.025 |
||
| 1 |
44 (34%) |
117 (27%) |
|
| 2-3 |
23 (18%) |
73 (16%) |
|
| Multiple |
61 (48%) |
251 (57%) |
|
|
Primary disease at BM |
0.007 |
||
| Controlled |
104 (81%) |
305 (70%) |
|
| Uncontrolled |
24 (19%) |
135 (31%) |
|
|
Extracranial disease at BM |
0.32 |
||
| Brain only |
22 (17%) |
97 (22%) |
|
| Bone + brain |
22 (17%) |
76 (17%) |
|
| Visceral + brain +/−bone |
76 (59%) |
245 (57%) |
|
| Other |
8 (6%) |
23 (5%) |
|
|
RPA at BM |
0.17 |
||
| 1 |
9 (7%) |
55 (12%) |
|
| 2 |
72 (56%) |
219 (50%) |
|
| 3 |
47 (37%) |
167 (39%) |
|
|
Craniotomy |
0.037 |
||
| Yes |
15 (12%) |
87 (20%) |
|
| No |
113 (88%) |
354 (80%) |
|
|
Trastuzumab at BM* |
|||
| Yes |
0 (0%) |
150 (34%) |
|
| No |
128 (100%) |
26 (5%) |
|
|
Hormonal therapy at BM* |
<0.001 |
||
| Yes |
72 (56%) |
100 (23%) |
|
| No |
56 (44%) |
341 (77%) |
|
|
Chemotherapy at BM* |
0.032 | ||
| Yes |
43 (34%) |
194 (44%) |
|
| No |
85 (66%) |
242 (55%) |
|
| Unknown | 0 (0%) | 5 (1%) | |
* Refers to treatments given on or after the date of first brain metastases.
Abbreviations: ER = estrogen receptor, HER2 = human epidermal growth factor receptor 2, KPS = Karnofsky performance status, BM = brain metastasis, RPA = recursive partitioning analysis.